Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

NCT06985316 is registered in ClinicalTrials.gov with Liu Huang as lead sponsor.

NCT NCT06985316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06985316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.
Lead sponsor
Liu Huang
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 19, 2025
Completion date
April 27, 2028
Enrollment
34 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

crc, colorectal cancer